These results indicate that the identified inducers of HMOX1 have the potential to ameliorate steatosis in vitro, further supporting the potential use of NRF2 inducers as therapeutic agents for NAFLD. Here, HMOX1 is linked to metabolic dysfunction-associated steatotic liver disease.